Re: ZEN-3694 Single Agent Trial Status

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

BearDownAZ

Rank: President [?]

Points: 25003 [?]

Votes: 68 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: ZEN-3694 Single Agent Trial Status

in response to

Re: ZEN-3694 Single Agent Trial Status

Hartland

posted on Jan 16, 2018 08:42PM

Hartland is right. The slide deck back in October first indicated that a 10 million share private placement was imminent.

2 Recommendations

Reply New Message

Prev Message Back To Forum Threaded View Next Message

Please to post a reply